Future directions in tumor marker technology for prostate cancer
Smith, J.A.; Scaletsky, R.
Urologic Clinics of North America 20(4): 771-777
1993
ISSN/ISBN: 0094-0143 PMID: 7505985 Document Number: 418449
This article assesses the likely role of PSA in the future management of patients with carcinoma of the prostate, taking into consideration new methods for measurement and assessment. In addition, novel tumor markers are discussed that may complement, or even perhaps replace, PSA.
Document emailed within 1 workday
Related Documents
Chiarodo, A. 1991: National Cancer Institute roundtable on prostate cancer: future research directions Cancer Research 51(9): 2498-2505Leewansangtong, S.; Soontrapa, S.; Tantiwong, A. 1999: Is prostate-specific antigen still the best tumor marker for prostate cancer? Journal of the Medical Association of Thailand 82(10): 1034-1040
Kamachi, S.; Sakurabayashi, I.; Kawai, T. 1984: Studies on prostate specific antigen, gamma-seminoprotein (gamma-Sm) as a tumor marker of prostatic cancer Rinsho Byori. Japanese Journal of Clinical Pathology 32(7): 781-785
Awada, A.; Klastersky, J. 2004: Ovarian cancer: state of the art and future directions European Journal of Gynaecological Oncology 25(6): 673-676
Mamounas, E.P.; Wieand, H.S.; Jones, J.; Wickerham, D.L.; Wolmark, N. 1997: Future directions in the adjuvant treatment of colon cancer Oncology 11(9 Suppl 10: 44-47
Kelsey, J.L. 1993: Breast cancer epidemiology: summary and future directions Epidemiologic Reviews 15(1): 256-263
Rodríguez Duarte, C. 1991: Prostate-specific antigen as a prostatic tumor marker. Analysis of results in 206 patients Archivos Espanoles de Urologia 44(6): 697-700
Perry, M.C. 1997: Future directions in the therapy of small cell lung cancer Chest Surgery Clinics of North America 7(1): 183-194
Comis, R.L.; Finley, R.S. 1999: Future directions in the treatment of non-small cell lung cancer Seminars in Oncology 26(6 Suppl 18: 14-18
Ozols, R.F.; Vermorken, J.B. 1997: Chemotherapy of advanced ovarian cancer: current status and future directions Seminars in Oncology 24(1 Suppl 2: S2
Rivlin, R.S. 2001: Nutrition and cancer prevention: new insights into the role of phytochemicals. Future directions Advances in Experimental Medicine and Biology 492: 255-262
Kos, T.; Aksoy, S.; Sendur, M.A.N.; Arik, Z.; Civelek, B.; Kandemir, N.; Ozdemir, N.Y.; Zengin, N.; Altundag, K. 2013: Variations in tumor marker levels in metastatic breast cancer patients according to tumor subtypes Journal of BUON: Official Journal of the Balkan Union of Oncology 18(3): 608-613
Hardt, P.D.; Ngoumou, B.K.; Rupp, J.; Schnell-Kretschmer, H.; Kloer, H.U. 2000: Tumor M2-pyruvate kinase: a promising tumor marker in the diagnosis of gastro-intestinal cancer Anticancer Research 20(6d): 4965-4968
Khan, M.O.; Ather, M.H. 2011: Chromogranin A--serum marker for prostate cancer JPMA. Journal of the Pakistan Medical Association 61(1): 108-111
Abbas, A.; Yang, G.; Fakih, M. 2010: Management of anal cancer in 2010. Part 2: current treatment standards and future directions Oncology 24(5): 417-424
Narita, D.; Cimpean, A.M.; Anghel, A.; Raica, M. 2006: Prostate-specific antigen value as a marker in breast cancer Neoplasma 53(2): 161-167
Nikoleishvili, D.; Pertia, A.; Tsintsadze, O.; Gogokhia, N.; Chkhotua, A. 2007: Down-regulation of p27(Kip 1) cyclin-dependent kinase inhibitor in prostate cancer: distinct expression in various prostate cells associating with tumor stage and grades Georgian Medical News 143: 34-38
Rich, S. 2007: Protecting the Next Generation: Promising Directions for a Better Future / Proteger la prochaine Generation: Directions prometteuses pour un meilleur avenir African Journal of Reproductive Health / La Revue Africaine de la Santé Reproductive 11(3): 13-17
Wong, S.S.; Wu, A.H.; Fritsche, H.A. 1987: Reassessment of creatine kinase BB as a marker for cancer of the prostate, breast, and lung Clinical Chemistry 33(6): 809-811
Kimura, E.; Murae, M.; Koga, R.; Odawara, Y.; Nakabayashi, Y.; Yokoyama, K.; Nakata, H.; Totake, T.; Ochiai, K.; Yasuda, M. 1984: Clinical significance of new tumor marker CA 125 in gynecological cancer--particularly usefulness in diagnosis of ovarian cancer Nihon Sanka Fujinka Gakkai Zasshi 36(11): 2121-2128